A Phase 3, Randomized, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of Dotinurad Compared With Allopurinol in Adult Participants With Hyperuricemia Associated With Gout
A Phase 3, Randomized, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of Dotinurad Compared With Allopurinol in Adult Participants With Hyperuricemia Associated With Gout
The primary objective of this study is to evaluate the efficacy of dotinurad in lowering serum uric acid (sUA) at Week 24 compared with allopurinol in adult participants with hyperuricemia associated with gout.
Inclusion Criteria:
Exclusion Criteria:
ClinicalTrials@crystalystx.com1-858-379-2316
Birmingham, Alabama 35233, United States
Gilbert, Arizona 85297, United States
Glendale, Arizona 85306, United States
Mesa, Arizona 85110, United States
San Bernardino, California 92408, United States
Chicago, Illinois 60640, United States
Indianapolis, Indiana 46202, United States
Overland Park, Kansas 66223, United States
Metairie, Louisiana 70006, United States
New Orleans, Louisiana 70124, United States
Rockville, Maryland 20852, United States
Saint Clair Shores, Michigan 48081, United States
Sterling Heights, Michigan 48313, United States
West Chester, Pennsylvania 19380, United States
North Charleston, South Carolina 29405, United States
Lewisville, Texas 75057, United States
Plońsk, Masovian Voivodeship 09-100, Poland
Warsaw, Masovian Voivodeship 00-872, Poland
Bialystok, Podlaskie Voivodeship 15-879, Poland
Wejherowo, Pomeranian Voivodeship 84-200, Poland
Seville, Sevilla 46010, Spain
tdavis@westcoastresearch.com925-413-1451
viviana@crtfi.com813-873-8102
manognya@ccrii.us312-791-3241
ekrambeck@delricht.com504-336-2667
bbolton@delricht.com225-412-0316
shahin@pioneerresearchsolutions.com713-333-9323